AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) Commences Clinical Studies For Its Point-Of-Care COVID-19 Neutralizing Antibodies Rapid Test

AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) has announced the commencement of ImmunoPass clinical trials. ImmunoPass is the company’s rapid point-of-care test that semi-quantitatively measures COVID-19 neutralizing antibody levels.

AXIM develop a rapid test for COVID-19 neutralizing antibodies

With various COVID-19 vaccines rolling out, immunity monitoring will be critical in determining vaccine effectiveness and how long it takes to get a booster shot. Since immunity against the virus doesn’t last forever, immunity monitoring is necessary and could continue for years even after mass vaccination globally. Most importantly, neutralizing antibody measuring will better understand how vaccine responses will hold up with time. Through this, researchers can understand when neutralizing antibody levels dip and the time when revaccination is ideal.

Notably, available antibody tests in the market currently don’t identify neutralizing antibodies. They instead measure antibodies binding to various virus parts but not necessarily those that neutralize it. As a result, AXIM® sought to address this shortcoming by developing a patent-pending rapid test called ImmunoPass. The test focuses on measuring neutralizing antibody levels that prevent SARS-CoBV-2. ImmunoPass is based on blocking human cell receptors’ interaction with the viral spike protein by mimicking the body’s virus neutralization process.

ImmunoPass offers better results compared to available tests

Interestingly, ImmunoPass has demonstrated significantly better SARS-CoV-2 neutralizing assays correlation compared to available antibody tests. Since ImmunoPass performs well with live virus-based assays, it serves as a low-cost alternative to current lab-based assays in monition vaccine recipients for neutralizing antibodies.

Despite clinical trials showing that COVID-19 vaccines could be successful with up to 95% effectiveness, there are still millions of people t6ahte will remain unprotected. As a result, neutralizing antibody testing could be vital in determining efficacy, thus showing when an individual is protected against SARS-CoV-2. Fascinatingly, AXIM®’s rapid diagnostic test for neutralizing antibody levels is the first such test used for measuring functional neutralizing antibodies believed to be vital in preventing SARS-CoV-2. Besides the rapid test for COVID-19 neutralizing antibodies, the company is developing rapid tests for early cancer detection and drugs that treat cancer.